SECTOR:

CNS

FUND/VEHICLE:

Pivotal US

INVESTMENT DATE:

2019

GEOGRAPHY:

North America

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

Karuna Therapeutics is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.